文献速递乳腺癌放疗放疗物理与技术

TARGIT-A试验亚组患者与医生、护士及BCCT.core软件对美容效果评价的5年一致性分析

Cosmetic outcome as rated by patients, doctors, nurses and BCCT.core software assessed over 5 years in a subset of patients in the TARGIT-A Trial.
PubMed 文献 · Radiat Oncol · 2018-04-13

该研究基于TARGIT-A随机试验亚组,比较患者、放疗医生、研究护士及BCCT.core软件四种美容效果评价体系在5年内的 agreement。结果显示两组各时间点均以优良评分居多,TARGIT-IORT组在第5年优良评分显著更高,但四种评价体系间一致性仅为中等(最高Kappa=0.46)。结论提示这些评价体系未必可互换使用,患者视角对美容效果结局最为重要。

要点

  • 四种美容评价体系间一致性仅为中等,最高Kappa=0.46出现在第1年护士与医生评分之间。
  • 各时间点两组均以优良美容效果评分居多,TARGIT-IORT组第5年优良评分显著更高。
  • 评价体系不可互换使用,患者自评对美容效果结局可能最为重要。

核心结论

  • 尽管两种治疗组及四种评价体系的总体结果相似,但评价者间一致性仅为中等,提示这些体系未必可互换使用。
  • 对于美容外观这类结局,患者的观点可能最为重要。

研究设计与样本

  • 基于随机TARGIT-A试验亚组患者,比较风险适应性单次术中放疗(TARGIT-IORT)与全乳外照射放疗(EBRT)。
  • 患者在放疗前及此后每年完成主观美容评估问卷,持续5年;同时使用基于数字照片的BCCT.core软件客观评分对称性、颜色和瘢痕。
  • 采用Kappa统计量评估一致性,采用广义估计方程评估纵向变化。

主要发现

  • 两组在所有时间点均以优良(EG)美容结果评分多于一般-差(FP)评分。
  • 接受TARGIT-IORT的患者较EBRT患者更常评为EG,但仅在 year 5 差异有统计学意义。
  • 四种评价体系间一致性仅为中等,最高为第1年护士与医生评分之间Kappa=0.46(p<0.001),95%CI(0.24, 0.68)。

关键数值与推荐

  • 护士与医生评分在第1年的一致性Kappa=0.46(p<0.001),95%CI(0.24, 0.68),为最高Kappa值。

临床怎么用

  • 临床解读美容效果时应认识到不同评价者及软件间一致性有限,不宜互换使用。
  • 患者自评应作为美容效果评价的重要参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this research was to assess agreement between four rating systems of cosmetic outcome measured in a subset of patients with early breast cancer participating in the randomised TARGIT-A trial. TARGIT-A compared risk-adapted single-dose intra-operative radiotherapy (TARGIT-IORT) to whole breast external beam radiotherapy (EBRT). METHODS: Patients, their Radiation Oncologist and Research Nurse completed a subjective cosmetic assessment questionnaire before radiotherapy and annually thereafter for five years. Objective data previously calculated by the validated BCCT.core software which utilizes digital photographs to score symmetry, colour and scar was also used. Agreement was assessed by the Kappa statistic and longitudinal changes were assessed by generalized estimating equations. RESULTS: Overall, an Excellent-Good (EG) cosmetic result was scored more often than a Fair-Poor (FP) result for both treatment groups across all time points, with patients who received TARGIT-IORT scoring EG more often than those who received EBRT however this was statistically significant at Year 5 only. There was modest agreement between the four rating systems with the highest Kappa score being moderate agreement which was between nurse and doctor scores at Year 1 with Kappa = 0.46 (p < 0.001), 95% CI (0.24, 0.68). CONCLUSION: Despite similar overall findings between treatment groups and rating systems, the inter-rater agreement was only modest. This suggests that the four rating systems utilized may not necessarily be used interchangeably and it is arguable that for an outcome such as cosmetic appearance, the patient's point of view is the most important. TRIAL REGISTRATION: TARGIT-A ISRCTN34086741 , Registered 21 July 2004, retrospectively registered.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Corica T, Nowak AK, Saunders CM, et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT.core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiat Oncol. 2018. PMID: 29653541. doi:10.1186/s13014-018-0998-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。